CancerAppy
Novel cancer therapeutic drugs
At CancerAppy, we specialize in cancer research, dedicated to discovering and developing new therapeutic targets. Our proprietary artificial intelligence methodology allows us to accelerate advancements in more effective cancer treatments
Driving innovation in breakthrough oncology treatments.
With our deep expertise in oncology and AI, we analyze vast amounts of multimodal data using advanced AI algorithms. This allows us to identify new therapeutic targets, discover lead compounds, understand their mechanisms of action, and explore potential drug combinations. Our technology also enables the development of next-generation antibody-drug conjugates (ADCs), driving more precise and effective cancer treatments.

We work in the early stage of the Drug Discovery Value Chain.

Our R&D Pipeline
At CancerAppy, we use AI-driven drug discovery to develop new cancer therapies, including novel ADCs (antibody-drug conjugates). Our pipeline moves from target discovery to preclinical development, bringing innovative treatments closer to patients.
News
Latest news about CancerAppy…
Anglonordic
CancerAppy was present at Anglonordic 2022. An event in which we had the opportunity to contact investors and companies in the biotechnology sector...
Tel Aviv – SOSA
We are going to stay in Tel Aviv from March 25th through March 28th looking to learn about entrepreneurship, new relationships and...
4YFN 2022
This week we will be attending the 4YFN in Barcelona as a company selected by @icex and @red.es. Do not hesitate to stop by our stand on Monday and...
Grant CPP2021-008597 funded by:

Grant TQ2020-011486 funded by:


Subvencionado por el CDTI

Somos cliente Enisa

